Adalimumab therapy used successfully for recalcitrant Hailey-Hailey disease

Chen, Ailynna; DaCunha, Matthew; Harms, Jessica L.

doi:10.1016/j.jdcr.2022.09.014

Cited by 7 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison to estradiol alone, microdialysis demonstrated that apremilast plus estrogen decreased extracellular VEGF in solid MCF-7 tumors in nude mice. Extracellular VEGF release in vitro supported in situ findings (17)(18)(19).…”

Section: Discussionsupporting

confidence: 65%

See 1 more Smart Citation

Apremilast Treatment of Cancer in Mice Tumorised with Breast Cancer: In Vivo Study

2023

JPTCP

View full text Add to dashboard Cite

It is widely accepted that vascular endothelial growth factor, often abbreviated as VEGF, is an important mediator in the process of tumor angiogenesis, which includes neovascularization in human breast cancer. Patients with either node-positive or node-negative breast cancer have a worse prognosis overall if there are high levels of VEGF in the tissue. It would seem logical to expect a poor prognosis given these circumstances. There is evidence that the partial estrogen receptor agonist apremilast may increase the quantity of VEGF mRNA that is generated in breast cancer cells, suggesting that hormones may regulate the amount of VEGF that is expressed. However, the findings of clinical studies show that apremilast increases average survival rates while reducing the incidence of metastases. These results seem to raise questions about apremilast's efficacy as an adjuvant treatment for estrogen-dependent breast cancer. In this study, we demonstrate for the first time that apremilast can lower extracellular VEGF levels in vivo using solid MCF-7 tumors in naked mice. Nothing like to this has ever been done. Following the injection of apremilast, the levels of extracellular VEGF seen in the cell culture conditions were dramatically decreased. The in vivo outcomes that were found were supported by these findings.

show abstract

Section: Discussionsupporting

confidence: 65%

“…Our results suggest that post-translational regulation may control extracellular VEGF. Apremilast prevents cells from producing or releasing extracellular VEGF (18). Longer VEGF isoforms are converted into soluble, bioactive forms via proteolysis.…”

Section: Discussionmentioning

confidence: 99%

Apremilast Treatment of Cancer in Mice Tumorised with Breast Cancer: In Vivo Study

2023

JPTCP

View full text Add to dashboard Cite

show abstract

Multiple drugs

2023

Reactions Weekly

View full text Add to dashboard Cite

Interleukin-17A immune pattern across genetic acantholytic and blistering disorders

Javid

Technau‐Hafsi

et al. 2023

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

There is a high therapeutic need for acantholytic and blistering genodermatoses. Cutaneous inflammation is a reasonable target, although the patterns are not yet fully elucidated. Here we investigated by immunohistochemistry whether IL-17A is expressed in the inflammatory infiltrate in 34 patients with Hailey-Hailey disease, Darier disease, junctional and dystrophic epidermolysis bullosa. There was a 5-7-fold increase in the number IL-17A positive cells in all patients’ samples as compared to the normal skin. IL-17A cells were present in the epidermal acantholytic areas and dermal inflammatory infiltrates in Hailey-Hailey and Darier disease. In epidermolysis bullosa samples positive cells were present at the dermal-epidermal junction zone. The IL-17A inflammatory pattern was validated by upregulation of downstream genes/proteins, S100A7, S100A8 and S100A9. These results suggest that IL-17A contributes to skin inflammation and could be a therapeutic target during inflammatory flares in these disorders.

show abstract

Adalimumab therapy used successfully for recalcitrant Hailey-Hailey disease

Cited by 7 publications

References 8 publications

Apremilast Treatment of Cancer in Mice Tumorised with Breast Cancer: In Vivo Study

Apremilast Treatment of Cancer in Mice Tumorised with Breast Cancer: In Vivo Study

Multiple drugs

Interleukin-17A immune pattern across genetic acantholytic and blistering disorders

Contact Info

Product

Resources

About